ベーチェット病

出版社: 文光堂
著者:
発行日: 2016-03-01
分野: 臨床医学:内科  >  膠原病/リウマチ
ISBN: 9784830620379
電子書籍版: 2016-03-01 (第1版第2刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:8~14営業日

7,344 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,344 円(税込)

第一線の専門家による,本邦初の「ベーチェット病」に関する成書!本書では,この25年で多大に進歩を遂げた,ベーチェット病に関する,遺伝学,免疫学的な背景から,粘膜皮膚,眼,関節,消化管,神経,血管の各症状や病変と,その予後と治療までの重要なテーマについて,第一線の専門家がわかりやすく解説した.特に病理所見や皮膚や眼,消化管などの症状についてはカラー写真を豊富に盛り込んだ.ベーチェット病診療医待望の,本邦初の成書.

目次

  • 表紙
  • 執筆者一覧
  • 目次
  • 1章 オーバービュー
  • 2章 ベーチェット病の遺伝学
  • 3章 免疫学的異常
  • 4章 ベーチェット病と自然免疫
  • 5章 ベーチェット病の病理学的特徴
  • 6章 粘膜皮膚病変
  • 7章 眼症状
  • 8章 関節病変
  • 9章 消化管病変
  • 10章 神経ベーチェット病
  • 11章 血管病変
  • 12章 予後と治療
  • 索引
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 オーバービュー

P.4 掲載の参考文献
4) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease : a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
11) International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-80.
14) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.

2章 ベーチェット病の遺伝学

P.15 掲載の参考文献
2) Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet's disease in Turkey. Ann Rheum Dis 2000 ; 59 : 622-5.
3) Kone-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al. Familial aggregation in Behcet's disease : high frequency in siblings and parents of pediatric probands. J Pediatr 1999 ; 135 : 89-93.
15) Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD, et al. Localization of the pathogenic gene of Behcet's disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci 2000 ; 41 : 3702-8.
18) Pervin K, Childerstone A, Shinnick T, Mizushima Y, van der Zee R, Hasan A, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol 1993 ; 15 : 2273-82.
22) O'Connor GM, McVicar D. The yin-yang of KIR3DL1/S1 : molecular mechanisms and cellular function. Crit Rev Immunol 2013 ; 33 : 203-18.
24) Kurhan-Yavuz S, Direskeneli H, Bozkurt N, Ozyazgan Y, Bavbek T, Kazokoglu H, et al. Anti-MHC autoimmunity in Behcet's disease : T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol 2000 ; 120 : 162-6.
31) Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Behcet's disease in Japanese patients. Clin Exp Rheumatol 2010 ; 28 (4 Suppl 60) : S39-44.
43) Haverkorn MJ, Goslings WR. Streptococci, ABO blood groups, and secretor status. Am J Hum Genet 1969 ; 21 : 360-75.
44) Filen S, Lahesmaa R. GIMAP Proteins in T-Lymphocytes. J Signal Transduct 2010 ; 2010 : 268589
48) Palomino-Morales RJ, Rojas-Villarraga A, Gonzalez CI, Ramirez G, Anaya JM, Martin J. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun 2008 ; 9 : 379-82.
55) Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S. Cytokines in Behcet's disease. J Rheumatol 1996 ; 23 : 321-2.
56) Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease ; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997 ; 24 : 128-32.
57) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
60) Zhang M, Xu WD, Wen PF, Liang Y, Liu J, Pan HF, et al. Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease : an updated meta-analysis. Mol Vis 2013 ; 19 : 1913-24.
64) Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999 ; 285 (5428) : 727-9.

3章 免疫学的異常

P.30 掲載の参考文献
4) Hamzaoui K, Hamzaoui A, Hentati F, Kahan A, Ayed K, Chabbou A, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behcet's disease. J Rheumatol 1994 ; 21 : 2301-6.
6) Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 1995 ; 132 : 901-7.
7) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease-a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
9) Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease. Clin Exp Rheumatol 2004 ; 22 : S59-63.
15) Kang EH, Kim JY, Takeuchi F, Kim JW, Shin K, Lee EY, et al. Associations between the HLA-A polymorphism and the clinical manifestation of Behcet's disease. Arthritis Res Ther 2011 ; 13 : R49.
16) Chung YM, Yeh TS, Sheu MM, Chen MS, Wen MS, Tsai HY, et al. Behcet's disease with ocular involvement in Taiwan : a joint survey of six major ophthalmological departments. J Formos Med Assoc 1990 ; 89 : 413-7.
17) Mizuki N, Ohno S, Ando H, Chen L, Palimeris GD, Stavropoulos-Ghiokas E, et al. A strong association between HLA-B*5101 and Behcet's disease in Greek patients. Tissue Antigens 1997 ; 50 : 57-60.
23) Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, et al. Neutrophil CD64 expression in Behcet's disease. J Rheumatol 2005 ; 32 : 849-52.
25) Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 : S19-24.
27) Matsumara N, Mizushima Y. Leukocyte movement and colchicine treatment in Behcet's disease. Lancet 1975 ; 2 : 813.
32) Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998 ; 161 : 5821-4.
35) Onder M, Bozkurt M, Gurer MA, Gulekon A, Sezgin P, Imir T. Natural cellular cytotoxicity in Behcet's disease. J Dermatol 1994 ; 21 : 239-43.
37) Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin Exp Immunol 1988 ; 71 : 126-31.
42) Yasuoka H, Yamaguchi Y, Mizuki N, Nishida T, Kawakami Y, Kuwana M. Preferential activation of circulating CD8+ and gammadelta T cells in patients with active Behcet's disease and HLA-B51. Clin Exp Rheumatol 2008 ; 26 : S59-63.
54) Ferrante A, Ciccia F, Principato A, Giardina AR, Impastato R, Peralta S, et al. A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behcet's disease. Clin Exp Rheumatol 2010 ; 28 : S27-30.
61) Kim J, Park JA, Lee EY, Lee YJ, Song YW, Lee EB. Imbalance of Th17 to Th1 cells in Behcet's disease. Clin Exp Rheumatol 2010 ; 28 : S16-9.
66) Hamzaoui K. Paradoxical high regulatory T cell activity in Behcet's disease. Clin Exp Rheumatol 2007 ; 25 : S107-13.
67) Hamzaoui K, Hamzaoui A, Houman H. CD4+ CD25+ regulatory T cells in patients with Behcet's disease. Clin Exp Rheumatol 2006 ; 24 : S71-8.
71) Direskeneli H, Keser G, D'Cruz D, Khamashta MA, Akoglu T, Yazici H, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behcet's disease. Clin Rheumatol 1995 ; 14 : 55-61.
73) Lee JH, Cho SB, Bang D, Oh SH, Ahn KJ, Kim J, et al. Human anti-alpha-enolase antibody in sera from patients with Behcet's disease and rheumatologic disorders. Clin Exp Rheumatol 2009 ; 27 : S63-6.
75) Briani C, Doria A, Marcolongo R, Tognon S, Ruggero S, Toffanin E, et al. Increased titres of IgM anti-heparan sulfate antibody in Behcet's disease. Clin Exp Rheumatol 2006 ; 24 : S104-7.
77) Direskeneli GS, Celet B, Eksioglu-Demiralp E, Direskeneli H. Human HSP 60 peptide responsive T cell lines are similarly present in both Behcet's disease patients and healthy controls. Immunol Lett 2001 ; 79 : 203-8.
78) de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behcet's disease patients and controls. Invest Ophthalmol Vis Sci 2000 ; 41 : 3480-4.
79) Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behcet's syndrome. Infect Immun 1991 ; 59 : 1434-41.

4章 ベーチェット病と自然免疫

P.45 掲載の参考文献
3) Consortium TFF. A candidate gene for familial Mediterranean fever. Nat Genet 1997 ; 17 : 25-31.
6) Denman AM, Fialkow PJ, Pelton BK, Salo AC, Appleford DJ, Gilchrist C. Lymphocyte abnormalities in Behcet's syndrome. Clin Exp Immunol 1980 ; 42 : 175-85.
8) Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behcet's disease and is associated with disease severity. Rheumatology (Oxford) 2004 ; 43 : 1028-33.
9) Celenligil-Nazliel H, Kansu E, Ebersole JL. Periodontal findings and systemic antibody responses to oral microorganisms in Behcet's disease. J Periodontol 1999 ; 70 : 1449-56.
10) Umit K, Gonca M, Ismail S, Salih P, Osman K, Hakan E, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease : a prospective clinical study. J Oral Pathol Med 2009 ; 38 : 410-5.
13) Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celic I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996 ; 39 : 2062-5.
14) Isogai E, Isogai H, Yokota K, Oguma K, Kimura K, Kubota T, et al. Experimental model for Behcet's disease in gnotobiotic mice infected with Streptococcus sanguis. In : Behcet's desease. Bang E, Lee ES, Lee S, eds. Design Mecca Publishing Co., Korea. 2001 : 133-8.
17) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease : a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
20) Sohn S, Lee ES, Bang D, Lee S. Behcet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998 ; 8 : 21-3.
23) Yokota K, Hayashi S, Araki Y, Isogai E, Kotake S, Yoshikawa K. Characterization of Streptococcus sanguis isolated from patients with Behcet's disease. Microbiol Immunol 1995 ; 39 : 729-32.
29) Hamzaoui K, Hamzaoui A, Hentati F, Kahan A, Ayed K, Chabbou A, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behcet's disease. J Rheumatol 1994 ; 21 : 2301-6.
30) Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of γδ T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006 ; 12 : 271-7.
35) Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, et al. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol 1997 ; 24 : 1332-6.
37) Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 (5 Suppl. 24) : S19-24.
38) Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, et al. Neutrophil CD64 expression in Behcet's disease. J Rheumatol 2005 ; 32 : 849-52.
42) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
43) Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease : high levels may indicate vascular involvement. Int J Dermatol 2009 ; 48 : 259-64.
45) Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behcet's disease. J Rheumatol 1990 ; 17 : 1428-9.
54) Aktas Cetin E, Cosan F, Cefle A, Deniz G. IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behcet's disease. Mod Rheumatol 2014 ; 24 : 802-7.
55) Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behcet's disease. Clin Exp Immunol 2012 ; 168 : 68-74.
56) Na SY, Park MJ, Park S, Lee ES. Up-regulation of Th17 and related cytokines in Behcet's disease corresponding to disease activity. Clin Exp Rheumatol 2013 ; 31 : 32-40.
58) Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A. Expression of Th-17 and RORγt mRNA in Behcet's Disease. Med Sci Monit 2011 ; 17 : CR227-34.
60) Fortune F, Walker J, Lehner T. The expression of γδ T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behcet's syndrome. Clin Exp Immunol 1990 ; 82 : 326-32.
63) Parlakgul G, Guney E, Erer B, Kihcaslan Z, Direskeneli H, Gul A, et al. Expression of regulatory receptors on γδ T cells and their cytokine production in Behcet's disease. Arthritis Res Ther 2013 ; 15 : R15.
65) Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin Exp Immunol 1988 ; 71 : 126-31.
66) Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease. Clin Exp Rheumatol 2004 ; 22 : S59-63.
70) Poulter LW, Lehner T. Immunohistology of oral lesions from patients with recurrent oral ulcers and Behcet's syndrome. Clin Exp Immunol 1989 ; 78 : 189-95.
72) Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T. Monocyte activity in Behcet's disease. Br J Rheumatol 1996 ; 35 : 424-9.
75) Castrichini M, Lazzerini PE, Gamberucci A, Capecchi PL, Franceschini R, Natale M, et al. The purinergic P2×7 receptor is expressed on monocytes in Behcet's disease and is modulated by TNF-α. Eur J Immunol 2014 ; 44 : 227-38.
81) Liang L, Tan X, Zhou Q, Zhu Y, Tian Y, Yu H, et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013 ; 54 : 402-14.
89) Inanc N, Mumcu G, Birtas E, Elbir Y, Yavuz S, Ergun T, et al. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. J Rheumatol 2005 ; 32 : 287-291.
90) Mumcu G, Inanc N, Aydin SZ, Ergun T. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (Suppl. 53) : S32-6.
91) Kim J, Im CH, Kang EH, Lee EY, Lee YJ, Park KS. Mannose-binding lectin gene-2 polymorphisms and serum mannose-binding lectin levels in Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (Suppl. 53) : S13-7.
94) Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behcet's disease : correlations with disease activity and severity. Isr J Med Sci 1995 ; 31 : 345-8.
107) Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011 ; 34 : 755-68.
114) Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003 ; 21 (4 suppl. 30) : S35-7.
118) Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 : 399-402.
119) Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-92.
123) Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behcet's disease. Clin Exp Rheumatol 2012 ; 30 : S115.
125) Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease : an open-label pilot study. Ann Rheum Dis 2012 ; 71 : 563-6.

5章 ベーチェット病の病理学的特徴

P.63 掲載の参考文献
1) Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloum M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 (suppl. 24) : S48-50.
3) Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selection expression by sera from patients with active Behcet's disease : moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999 ; 91 : 330-7.
5) Mantas C, Direskeneli H, Oz D, Yavuz S, Akoglu T. IL-8 producing cells in patients with Behcet's disease. Clin Exp Rheumatol 2000 ; 18 : 249-51.
10) Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999 ; 162 : 4328-35.
14) Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 1995 ; 132 : 901-7.
16) Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet's disease in Japan : ophthalmologic aspects. Trans Am Ophthalmol Soc 1979 ; 77 : 225-79.
17) Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, et al. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. Arthritis Res Ther 2009 ; 11 : R17.
21) Hirohata S, Kikuchi H. Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (2 Suppl 53) : S91-5.
23) Koklu S, Yuksel O, Onur I, Unverdi S, Biyikoglu I, Akbal E, et al. Ileocolonic involvement in Behcet's disease : endoscopic and histological evaluation. Digestion 2010 ; 81 : 214-7.
24) Baba S, Morioka S. Treatment of intestinal Behcet's disease. In : Inaba G, ed. Behcet's Disease : Pathogenetic mechanism and clinical future. Japan Medical Research Foundation publication ; no.18, University of Tokyo Press, Tokyo, 1982 : 559-570.

6章 粘膜皮膚病変

P.72 掲載の参考文献
1) Bang D, Lee ES, Lee S. Behcet's disease. Asian Skin and Skin Diseases Special Book of the 22nd World Congress of Dermatology, May 24-29, 2011, Seoul. MEDrang, Inc, Seoul. 2011 : 313-25.
6) Bang D, Honma T, Saito T, Nakagawa S, Ueki H, Lee S. Ultrastructure of vascular changes in cutaneous manifestations of Behcet's disease. Acta Derm Venereol 1988 ; 68 : 33-40.
8) Nazzaro P. Cutaneous manifestations of Behcet's disease. In : Behcet's disease. International Symposium on Behcet's disease, Rome, 1964. Monacelli M, Nazzaro P, eds. S Karger, Basel. 1966 : 15-41.
9) International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-80.
10) International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD) : a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014 ; 28 : 338-47.
11) Kurokawa MS, Yoshikawa H, Suzuki N. Behcet's disease. Semin Respir Crit Care Med 2004 ; 25 : 557-68.
16) Kerkeni N, Zaraa I, Ayachi J, El Euch D, Mokni M, Ben Osman A. Behcet's disease : A profile of mucocutaneous features. Acta Dermatovenerol Alp Pannonica Adriat 2010 ; 19 : 11-5.
20) Plotkin GR. Miscellaneous clinical manifestations, Part II : Gastrointestinal, hepatic, splenic, pancreatic, genitourinary, and dermatologic features. In Behcet's disease : A contemporary synopsis. Plotkin GR, Calabro JJ, O'Duffy JD, eds. Futura Publishing Co., INC, New York. 1988 : 257-68.
27) Kim HJ, Bang D, Lee SH, Yang DS, Kim DH, Lee KH, et al. Behcet's syndrome in Korea : a look at the clinical picture. Yonsei Med J 1988 ; 29 : 72-8.
35) Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet's disease in Iran : analysis of 6500 cases. Int J Rheum Dis 2010 ; 13 : 367-73.
38) Roett MA, Mayor MT, Uduhiri KA. Diagnosis and management of genital ulcers. Am Fam Physician 2012 ; 85 : 254-62.
42) Quere I, Leizorovicz A, Galanaud JP, Presles E, Barrellier MT, Becker F, et al. Superficial venous thrombosis and compression ultrasound imaging. J Vasc Surg 2012 ; 56 : 1032-8.e1.
43) Jung JY, Kim DY, Bang D. Leg ulcers in Behcet's disease. Br J Dermatol 2008 ; 158 : 178-9.
46) Dilgen N, Konice M, Aral O, Ocal L, Inanc M, Gul A. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease : confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 1993 ; 52 : 823-5.

7章 眼症状

P.87 掲載の参考文献
1) al-Aboosi MM, al Salem M, Saadeh A, al-Jamal M, Hijawi M, Khammash M, et al. Behcet's disease : clinical study of Jordanian patients. Int J Dermatol 1996 ; 35 : 623-5.
3) Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, et al. Behcet's disease in Israel : the influence of ethnic origin on disease expression and severity. J Rheumatol 2001 ; 28 : 1033-6.
4) Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 ; 82 : 60-76.
5) Mousa AR, Marafie AA, Rifai KM, Dajani AI, Mukhtar MM. Behcet's disease in Kuwait, Arabia. A report of 29 cases and a review. Scand J Rheumatol 1986 ; 15 : 310-32.
6) Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet's disease : An analysis of 880 patients. Am J Ophthalmol 2004 ; 138 : 373-80.
10) Atmaca LS, Batioglu F. The efficacy of cyclosporin-a in the treatment of Behcet's disease. Ophthalmic Surg 1994 ; 25 : 321-7.
11) Ozdal PC, Ortac S, Taskintuna I, Firat E. Posterior segment involvement in ocular Behcet's disease. Eur J Ophthalmol 2002 ; 12 : 424-31.
12) Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet's disease in Japan : ophthalmologic aspects. Trans Am Ophthalmol Soc 1979 ; 77 : 225-79.
15) 稲葉裕 : ベーチェット病全国疫学調査-患者数の推計. 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 研究報告書. ベーチェット病に関する調査研究. 平成16年度総括・分担研究報告書, 89-90, 2005.
16) 大野重明, 蕪城俊克, 北市伸義, 他. ベーチェット病眼病変診療ガイドライン作成委員会. Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426. <http://www.nichigan.or.jp/member/guideline/behcet.jsp>
19) Al-Dhibi H, Abouammoh M, Al-Harthi E, Al-Gaeed A, Larsson J, Abboud E, et al. Macular hole in Behcet's disease. Indian J Ophthalmol 2011 ; 59 : 359-62.
24) Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 1997 ; 104 : 701-5.
29) Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Behcet's disease in Japanese patients. Clin Exp Rheumatol 2010 ; 28 (4 Suppl 60) : S39-44.
31) Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, et al. Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 2004 ; 111 : 810-5.
32) Kacmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, et al. Ocular inflammation in Behcet disease : incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 2008 ; 146 : 828-36.
37) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
43) Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease : an open-label trial. Arthritis Rheum 2005 ; 52 : 2478-84.
46) Almoznino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behcet's disease : a case report and review of the literature. Clin Exp Rheumatol 2007 ; 25 (4 Suppl 45) : S99-102.
51) Abalos-Medina GM, Sanchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E. Successful use of infliximab in a patient with neuro-Behcet's disease. Int J Rheum Dis 2009 ; 12 : 264-6.
57) Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 ; 87 : 423-31.
63) Okada AA, Wakabayashi T, Morimura Y, Kawahara S, Kojima E, Asano Y, et al. Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol 2003 ; 87 : 968-71.

8章 関節病変

P.96 掲載の参考文献
3) Ben-Dov I, Zimmerman J. Deforming arthritis of the hands in Behcet's disease. J Rheumatol 1982 ; 9 : 617-8.
4) Benamour S, Zeroual B, Alaoui FZ. Joint manifestations in Behcet's disease. A review of 340 cases. Rev Rhum Engl Ed 1998 ; 65 : 299-307.
5) Vernon-Roberts B, Barnes CG, Revell PA. Synovial pathology in Behcet's syndrome. Ann Rheum Dis 1978 ; 37 : 139-45.
9) Armas JB, Davies J, Davis M, Lovell C, McHugh N. Atypical Behcet's disease with peripheral erosive arthropathy and pyoderma gangrenosum. Clin Exp Rheumatol 1992 ; 10 : 177-80.
10) Duzgun N, Ates A. Erosive arthritis in a patient with Behcet's disease. Rheumatol Int 2003 ; 23 : 265-7.
11) Kotter I, Durk H, Eckstein A, Zierhut M, Fierlbeck G, Saal JG. Erosive arthritis and posterior uveitis in Behcet's disease : treatment with interferon alpha and interferon gamma. Clin Exp Rheumatol 1996 ; 14 : 313-5.
15) Crozier F, Arlaud J, Tourniaire P, Bodiou Y, Christides C, Paris M, et al. Manubrio-sternal arthritis and Behcet's disease : report of 3 cases. J Radiol 2003 ; 84 : 1978-81.
16) Chang HK, Lee DH, Jung SM, Choi SJ, Kim JU, Choi YJ, et al. The comparison between Behcet's disease and spondyloarthritides : does Behcet's disease belong to the spondyloarthropathy complex? J Korean Med Sci 2002 ; 17 : 524-9.
21) Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, et al. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. Arthritis Res Ther 2009 ; 11 : R17.
22) Nanke Y, Kotake S, Momohara S, Tateishi M, Yamanaka H, Kamatani N. Synovial histology in three Behcet's disease patients with orthopedic surgery. Clin Exp Rheumatol 2002 ; 20 (4 Suppl 26) : S35-9.
26) Ceccarelli F, Priori R, Iagnocco A, Coari G, Accorinti M, Pivetti Pezzi P, et al. Knee joint synovitis in Behcet's disease : a sonographic study. Clin Exp Rheumatol 2007 ; 25 : S76-9.
28) Sahin M, Yildiz M, Tunc SE, Cerci S, Suslu H, Cure E, et al. The usefulness of Tc-99m-MDP bone scintigraphy in detection of articular involvement of Behcet's disease. Ann Nucl Med 2006 ; 20 : 649-53.
29) Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-92.

9章 消化管病変

P.106 掲載の参考文献
7) Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease : a single center experience in Korea. J Korean Med Sci 2009 ; 24 : 52-6.
21) Koklu S, Yuksel O, Onur I, Unverdi S, Biyikoglu I, Akbal E, et al. Ileocolonic involvement in Behcet's disease : endoscopic and histological evaluation. Digestion 2010 ; 81 : 214-7.
35) Baba S, Morioka S. Treatment of Intestinal Behcet disease. In : Inaba G, editor. Behcet's disease. University of Tokyo Press, Tokyo 1982 : 559-70.
39) ベーチェット病に関する調査研究班. 腸管ベーチェット病診療ガイドライン平成21年度案-コンセンサス・ステートメントに基づく-. 難治性疾患克服研究事業厚生労働省研究費補助金 平成20~22年度総括・分担研究報告書, 2011
44) Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor α antibody. Gut 2001 ; 49 : 725-8.
45) Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behcet's disease with infliximab : rapid healing of Behcet's ulcer with infliximab. Clin Rheumatol 2007 ; 26 : 1383-5.
50) Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P ; French Network of Pharmacovigilance Centers. Arterial and venous thromboembolic events during anti-TNF therapy : a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009 ; 19 : 355-64.
56) 山名征三, 青井克行 (厚生省特定疾患ベーチェット病調査研究班). ベーチェット病の術後合併症の予防-その2. 平成4年度研究業績. 1993 : 163-5.
59) Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013 ; 58 : 496-503.

10章 神経ベーチェット病

P.123 掲載の参考文献
3) Serdaroglu P. Behcet's disease and the nervous system. J Neurol 1998 ; 245 : 197-205.
8) Akman-Demir G, Serdaroglu P, Tasci B. The Neuro-Behcet Study Group. Clinical patterns of neurological involvement in Behcet's disease : evaluation of 200 patients. Brain 1999 ; 122 : 2171-82.
12) Al-Araji A, Kidd DP. Neuro-Behcet's disease : epidemiology, clinical characteristics, and management. Lancet Neurol 2009 ; 8 : 192-204.
18) Houman MH, Hamzaoui-B'Chir S, Ben Ghorbel I, Lamloum M, Ben Ahmed M, Abdelhak S, et al. Neurologic manifestations of Behcet's disease : analysis of a series of 27 patients. Rev Med Interne 2002 ; 23 : 592-606.
28) Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, et al. CNS involvement in neuro-Behcet syndrome : an MR study. AJNR Am J Neuroradiol 1999 ; 20 : 1015-24.
29) Hirohata S, Takeuchi A, Miyamoto T. Elevated levels of interleukin 6 in cerebrospinal fluid from patients with Neuro-Behcet's syndrome. In : Behcet's disease. O'Duffy JD, Kokmen E, eds. Marcel Dekker, New York. 1991 : 369-76.
30) Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, et al. Successful treatment of refractory neuro-Behcet's disease with infliximab : a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007 ; 66 : 136-7.
31) Akman-Demir G, Tuzun E, Icoz S, Yesilot N, Yentur SP, Kurtuncu M, et al. Interleukin-6 in neuro-Behcet's disease : association with disease subsets and long-term outcome. Cytokine 2008 ; 44 : 373-6.
35) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
36) Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease : an open-label trial. Arthritis Rheum 2005 ; 52 : 2478-84.
38) Hirohata S, Kamoshita H, Taketani T. Spontaneous remission of meningoencephalitis in Behcet's disease. J Rheumatol 1989 ; 16 : 1283-4.
40) Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro- Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003 ; 528 : 575-8.
42) Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behcet's disease with infliximab. J Rheumatol 2005 ; 32 : 181-3.
47) Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behcet treated by tocilizumab : a case report. Clin Exp Rheumatol 2012 ; 30 (3 Suppl 72) : S73-5.

11章 血管病変

P.137 掲載の参考文献
4) Lie JT. Vascular involvement in Behcet's disease : arterial and venous and vessels of all sizes. J Rheumatol 1992 ; 19 : 341-3.
5) Duzgun N, Ates A, Aydintug OT, Demir O, Olmez U. Characteristics of vascular involvement in Behcet's disease. Scand J Rheumatol 2006 ; 35 : 65-8.
6) Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloun M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behcet's disease. Clin Exp Rhewmatol 2001 ; 19 (5 Suppl 24) : S48-50.
12) Hamza M. Large artery involvement in Behcet's disease. J Rheumatol 1987 ; 14 : 554-9.
13) Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behcet's disease. J Rheumatol 1992 ; 19 : 402-10.
14) Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A. Vascular involvement in Behcet's disease : 8-year audit. World J Surg 1994 ; 18 : 948-53.
15) Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 ; 82 : 60-76.
18) Kabbaj N, Benjelloun G, Gueddari FZ, Dafiri R, Imani F. Vascular involvements in Behcet disease. Based on 40 patient records. J Radiol 1993 ; 74 : 649-56.
24) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
25) Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease : high levels may indicate vascular involvement. Int J Dermatol 2009 ; 48 : 259-64.
28) Hirohata S, Kikuchi H. Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behcet's disease. Clin Exp Rheumatol 2009 ; 27 : S91-5.
33) Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, Yazganoglu K, Disci R, Erzengin D, et al. Vascular involvement in Behcet's disease : a retrospective analysis of 2319 cases. Int J Dermatol 2006 ; 45 : 919-21.
34) 小池茂文, 松本興治, 小久保光治, 森義雄, 村川真司, 広瀬光男. Bechet病に合併した腹部大動脈瘤術後に発生した大動脈十二指腸瘻の1例と本邦報告95例のBechet 病動脈瘤について. 日本外科学会雑誌 1988 ; 89 : 945-51.
45) International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-80.
47) Mader R, Ziv M, Adawi M, Mader R, Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999 ; 26 : 2404-8.
48) Lenk N, Ozet G, Alli N, Coban O, Erbasi S. Protein C and protein S activities in Behcet's disease as risk factors of thrombosis. Int J Dermatol 1998 ; 37 : 124-5.
49) Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behcet's disease. J Int Med Res 1998 ; 26 : 206-8.
50) Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, et al. Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol 2005 ; 23 : S53-8.
51) Bassyouni IH, Gamal S, Talaat RM, Siam I. Autoantibodies against complement C1q in patients with Behcet's disease : association with vascular involvement. Mod Rheumatol 2014 ; 24 : 316-20.
57) Nakano H, Oka H, Matsuda T, Ooka S, Imamura Y, Suzuki T, et al. Behcet's disease with vascular involvement : the contribution of anticardiolipin antibodies and thrombomodulin. Adv Exp Med Biol 2003 ; 528 : 395-8.
58) Temizoz O, Genchellac H, Yekeler E, Demir MK, Unlu E, Ozdemir H. CT-angiographic demonstration of hepatic collateral pathways due to superior vena cava obstruction in Behcet disease. Diagnostic and interventional radiology (Ankara, Turkey) 2010 ; 16 : 302-5.
65) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
68) Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P. Arterial and venous thromboembolic events during anti-TNF therapy : a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009 ; 19 : 355-64.
72) Yamana S, Murashita J, Ishibe Y, Aoi K. A case of vasculo-Behcet's disease with pseudoaneurism replaced with artificial vessel using prednisolone. Studies on Behcet's disease (Behcet's disease Research Committee of Japan, Ministry of Welfare, Japan 1991), 1992 : 158-60.
73) Yamana S, Aoki K, Yamanishi Y, Yamaguchi M. Rupture of postoperative pseudoaneurism and successful reoperation with artificial vessel under the administration of prednisolone. Studies on Behcet's disease (Behcet's disease Research Committee of Japan, Ministry of Welfare, Japan 1995), 1996 : 104-5.
77) Dogan SM, Birdane A, Korkmaz C, Ata N, Timuralp B. Right ventricular thrombus with Behcet's syndrome : successful treatment with warfarin and immunosuppressive agents. Tex Heart Inst J 2007 ; 34 : 360-2.

12章 予後と治療

P.149 掲載の参考文献
1) Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, et al. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset : long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 2010 ; 49 : 173-7.
5) Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 ; 82 : 60-76.
11) Levy-Clarke G, Jabs DA, Read RW, Rosenbaum J T, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014 ; 121 : 785-96 e3.
13) Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease : a single center experience in Korea. J Korean Med Sci 2009 ; 24 : 52-6.
17) Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-α antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009 ; 48 : 1012-3.
25) Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003 ; 528 : 575-8.
27) 稲葉裕, 黒沢美智子, 藤野雄次郎, 大野重昭, 坂根剛, 中江公裕 : ベーチェット病の予後調査 (中間報告). 厚生省特定疾患調査研究事業特定疾患に関する疫学研究班平成10年度研究業績. 1998 : 165-8.
32) Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001 ; 29 : 335-6.
33) Kotter I, Gunaydin I, Batra M, Vonthein R, Stubiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporin A (CSA) than under other medications : results of a retrospective analysis of 117 cases. Clin Rheumatol 2006 ; 25 : 482-6.
40) Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease : review of the literature. Semin Arthritis Rheum 2004 ; 33 : 320-35.
41) Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 ; 128 : 443-50.

最近チェックした商品履歴

Loading...